Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. 2000. Polymorphisms of UDP-glucurono- syltransferase gene and irinotecan toxicity: a pharmacogenetic ana- lysis. Cancer Res. 60(24):6921–6926.
Basit A, Neradugomma NK, Wolford C, Fan PW, Murray B, Takahashi RH, Khojasteh SC, Smith BJ, Heyward S, Totah RA, et al. 2020. Characterization of differential tissue abundance of major non-CYP enzymes in human. Mol Pharm. 17(11):4114–4124.
Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. 2005. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 11(3):1226–1236.
Cecchin E, Innocenti F, D’Andrea M, Corona G, De Mattia E, Biason P,Buonadonna A, Toffoli G. 2009. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluo- rouracil, leucovorin, and irinotecan. J Clin Oncol. 27(15):2457–2465.
Chen K, Jin M, Zhu Y, Jiang Q, Yu W, Ma X, Yao K. 2006. Genetic poly- morphisms of the uridine diphosphate glucuronosyltransferase 1A7 and colorectal cancer risk in relation to cigarette smoking and alcohol drinking in a Chinese population. J Gastroenterol Hepatol. 21(6): 1036–1041.
Chen X, Liu L, Guo Z, Liang W, He J, Huang L, Deng Q, Tang H, Pan H, Guo M, et al. 2017. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer: a meta- analysis. Cancer Chemother Pharmacol. 79(6):1109–1117.
Ciotti M, Basu N, Brangi M, Owens IS. 1999. Glucuronidation of 7-ethyl- 10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyl- transferases encoded at the UGT1 locus. Biochem Biophys Res Commun. 260(1):199–202. eng.
Cui C, Shu C, Cao D, Yang Y, Liu J, Shi S, Shao Z, Wang N, Yang T, Liang H, et al. 2016. UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens. Oncol Lett. 12(5):4231–4237.
de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. 2018. Individualization of Irinotecan treatment: a review of pharmacokinet- ics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 57(10):1229–1254.
Gagn´e JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. 2002. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamp- tothecin (SN-38). Mol Pharmacol. 62(3):608–617.
Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. 1997. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol. 80(2):91–96.
Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, Sawada J. 2001. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuroni- dation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica. 31(10): 687–699.
Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, et al. 2013. UGT1A1*6,1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci. 104(12):1662–1669.
Hirose K, Yamashita K, Takada H, Kaneda N, Fukami K, Maruo E, Kitamura M, Hasegawa J, Maeda Y. 2014. Usefulness of one-point plasma SN- 38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration. Int J Clin Oncol. 19(2): 397–402.
Hu DG, Marri S, Mackenzie PI, Hulin JA, McKinnon RA, Meech R. 2021. The expression profiles and deregulation of UDP-glycosyltransferase (UGT) genes in human cancers and their association with clinical out- comes. Cancers (Basel). 13(17):4491.
Huang CS, Luo GA, Huang ML, Yu SC, Yang SS. 2000. Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. Pharmacogenetics. 10(6):539–544.
Huang YH, Galijatovic A, Nguyen N, Geske D, Beaton D, Green J, Green M, Peters WH, Tukey RH. 2002. Identification and functional character-ization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics. 12(4):287–297.
Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, et al. 2013. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinote- can-based chemotherapy. Tohoku J Exp Med. 229(2):107–114.
Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y. 2004. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet. 49(3):123–128.
Iyer L, Hall D, Das S, Mortell MA, Ram´ırez J, Kim S, Di Rienzo A, Ratain MJ. 1999. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther. 65(5):576–582.
Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S-i, Sakaki T, Yokoi T. 2009. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos. 37(8):1759–1768.
Jinno H, Saeki M, Tanaka-Kagawa T, Hanioka N, Saito Y, Ozawa S, Ando M, Shirao K, Minami H, Ohtsu A, et al. 2003. Functional characteriza- tion of wild-type and variant (T202I and M59I) human UDP-glucuro- nosyltransferase 1A10. Drug Metab Dispos. 31(5):528–532.
Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J. 2003. Glucuronidation of 7- ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irino- tecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 31(1):108–113.
Maruo Y, Takahashi H, Matsui K, Sato H, Takeuchi Y. 2010. Phase II drug metabolism and individualized drug therapy: a focus on functional genetic variation in UDP-glucuronosyltransferases. CPPM. 8(2): 146–166.
Mimura Y, Maruo Y, Ohta Y, Sato H, Takeuchi Y. 2011. Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP- glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 109(6): 486–493.
Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. 2005. UDP-glucuronosyl- transferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos. 33(5):672–675.
Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, et al. 2011. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell TOXICOLOGY MECHANISMS AND METHODS 9 lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol. 6(1):121–127.
Oguri T, Takahashi T, Miyazaki M, Isobe T, Kohno N, Mackenzie PI, Fujiwara Y. 2004. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 24(5A): 2893–2896.
Sandanaraj E, Jada SR, Shu X, Lim R, Lee SC, Zhou Q, Zhou S, Goh BC, Chowbay B. 2008. Influence of UGT1A9 intronic I399C > T polymorph- ism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J. 8(3):174–185.
Strassburg CP, Manns MP, Tukey RH. 1998. Expression of the UDP-glucur- onosyltransferase 1A locus in human colon. Identification and charac- terization of the novel extrahepatic UGT1A8. J Biol Chem. 273(15): 8719–8726.
Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. 2002. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut. 50(6):851–856.
Sun L, Li M, Zhang L, Teng X, Chen X, Zhou X, Ma Z, Qi L, Wang P. 2017. Differences in UGT1A1 gene mutations and pathological liver changes between Chinese patients with Gilbert syndrome and Crigler-Najjar syndrome type II. Medicine (Baltimore). 96(45):e8620.
Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. 2008. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5’- diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 103(2):131–136.
Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. 1998. Inhibition of intestinal microflora b-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol. 42(4):280–286.
Teh LK, Hashim H, Zakaria ZA, Salleh MZ. 2012. Polymorphisms of UGT1A1*6, UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia. Indian J Med Res. 136(2):249–259.
Teng HC, Huang MJ, Tang KS, Yang SS, Tseng CS, Huang CS. 2007. Combined UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert’s syndrome in Taiwanese adults. Clin Genet. 72(4):321–328.
Thibaudeau J, L´epine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, T^etu B, Jacob S, Perusse L, et al. 2006. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 66(1):125–133.
Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, Guillemette C. 2018. Quantitative profiling of the UGT tran- scriptome in human drug-metabolizing tissues. Pharmacogenomics J. 18(2):251–261.
Troberg J, Jarvinen E, Ge GB, Yang L, Finel M. 2017. UGT1A10 is a high activity and important extrahepatic enzyme: why has its role in intes- tinal glucuronidation been frequently underestimated? Mol Pharm. 14(9):2875–2883.
Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 40: 581–616.
Tziotou M, Kalotychou V, Ntokou A, Tzanetea R, Armenis I, Varsou M,Konstantopoulos K, Tsavaris N, Rombos Y. 2014. Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity. Ecancermedicalscience. 8:428.
Valenzuela Jimenez B, Gonzalez Sales M, Escudero Ortiz V, Martinez Navarro E, Perez Ruixo C, Rebollo Liceaga J, Gonzalez Manzano R, Perez Ruixo JJ. 2013. Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokinetics of irinotecan, SN-38 and SN-38G. Farm Hosp. 37(2):111–127.
Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. 2003. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidat- ing enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 307(1):117–128.
Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, Strassburg CP. 2001. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology. 121(5):1136–1144.
Weismuller TJ, Zhou T, Kalthoff S, Lenzen H, Manns MP, Strassburg CP. 2020. Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary scleros- ing cholangitis. Liver Int. 40(7):1645–1654.
Xiao L, Zhu L, Li W, Li C, Cao Y, Ge G, Sun X. 2018. New insights into SN-38 glucuronidation: evidence for the important role of UDP glu- curonosyltransferase 1A9. Basic Clin Pharmacol Toxicol. 122(4): 424–428.
Zhang H, Wolford C, Basit A, Li AP, Fan PW, Murray BP, Takahashi RH, Khojasteh SC, Smith BJ, Thummel KE, et al. 2020. Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine. Drug Metab Dispos. 48(7):528–536.
Zhang W, Liu W, Innocenti F, Ratain MJ. 2007. Searching for tissue-spe- cific expression pattern-linked nucleotides of UGT1A isoforms. PLoS One. 2(4):e396.
Zhang Y, Hou J, Feng F, Li D, Jiang Q, Li X, Zhao Q, Li BA. 2017. Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: a systematic review and network meta-analysis. Oncotarget. 8(39):66371–66381.
論文の公開元へ
